Innovative Considerations on a Phase 2a Dose-Finding Strategy Using Bayesian Methods and McP-Mod

Trials - United Kingdom
doi 10.1186/1745-6215-16-s2-p204
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Effective Sample Size for Computing Prior Hyperparameters in Bayesian Phase I–II Dose-Finding

Clinical Trials
MedicinePharmacology
2014English

A Bayesian Dose-Finding Design Incorporating Toxicity Data From Multiple Treatment Cycles

Statistics in Medicine
EpidemiologyStatisticsProbability
2016English

A Bayesian Dose-Finding Design for Drug Combination Clinical Trials Based on the Logistic Model

Pharmaceutical Statistics
StatisticsProbabilityPharmacology
2014English

A Bayesian Dose Finding Design for Oncology Clinical Trials of Combinational Biological Agents

Journal of the Royal Statistical Society. Series C: Applied Statistics
UncertaintyStatisticsProbability
2013English

A Dose-Schedule Finding Design for Phase I-Ii Clinical Trials

Journal of the Royal Statistical Society. Series C: Applied Statistics
UncertaintyStatisticsProbability
2015English

Finding Convincing Arguments Using Scalable Bayesian Preference Learning

Transactions of the Association for Computational Linguistics
2018English

A Bayesian Dose Finding Design for Clinical Trials Combining a Cytotoxic Agent With a Molecularly Targeted Agent

Journal of the Royal Statistical Society. Series C: Applied Statistics
UncertaintyStatisticsProbability
2014English

Considerations on Finding the Rolling and Spinning Friction Coefficients

MATEC Web of Conferences
Materials ScienceEngineeringChemistry
2018English

Development of a Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose-Finding Study

Journal of Clinical Pharmacology
Pharmacology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy